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Abstract
Background—Chagas disease is caused by the parasite Trypanosoma cruzi and endemic in
much of Latin America. With increased globalization and immigration, it is a risk in any country
due in part to congenital transmission. The frequency of congenital transmission is unclear.
Objective—To assess the frequency of congenital transmission of T. cruzi.
Search Strategy—PubMed, Journals@Ovid Full Text, EMBASE, CINAHL, Fuente Academica
and BIREME databases were searched using seven search terms related to Chagas disease or
Trypanosoma cruzi and congenital transmission.
Selection Criteria—The inclusion criteria were the following: Dutch, English, French,
Portuguese or Spanish language; case report, case series or observational study; original data on
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congenital T. cruzi infection in humans; congenital infection rate reported or it could be derived.
This systematic review included 13 case reports/series and 51 observational studies.
Data Collection and Analysis—Two investigators independently collected data on study
characteristics, diagnosis and congenital infection rate. The principal summary measure – the
congenital transmission rate – is defined as the number of congenitally infected infants divided by
the number of infants born to infected mothers. A random effects model was utilized.
Main Results—The pooled congenital transmission rate was 4.7% (95% confidence interval:
3.9–5.6%). Endemic countries had a higher rate of congenital transmission compared to non-
endemic (5.0% vs. 2.7%).
Conclusions—Congenital transmission of Chagas disease is a global problem. Overall risk of
congenital infection in infants born to infected mothers is about 5%. The congenital mode of
transmission requires targeted screening to prevent future cases of Chagas disease.
Keywords
Trypanosoma cruzi; congenital infection; Chagas disease; systematic review; meta-analysis
Introduction
Chagas disease, or American trypanosomiasis, is caused by the protozoan parasite
Trypanosoma cruzi. It is a major cause of morbidity and mortality in the Americas and an
estimated 9 million persons are currently infected.1,2 T. cruzi is primarily transmitted by the
Triatomine insect vector (also called the kissing bug), blood transfusion, organ transplant,
congenital infection and oral transmission from food contaminated with insect feces.3
Reductions in vector-borne transmission risk in many countries due to large-scale vector
control4 have focused attention on other modes of transmission such as congenital
transmission. This mode of transmission is of concern worldwide, due to the migration of
people from Chagas endemic countries of Latin America.5
The majority of pregnant women with Chagas is chronically infected and asymptomatic but
may be at increased risk of preterm birth, low-birth weight and stillbirth.6 Infected newborns
can develop a symptomatic infection (congenital Chagas disease) after birth characterized by
hepato-splenomegaly, meningoencephalitis, myocarditis, anasarca or anemia; however, the
majority of infants present with asymptomatic congenital T. cruzi infection, making it highly
unlikely they will be diagnosed unless the presence of the infection is specifically sought. As
many as 30% of infected infants will progress to the life-threatening cardiac or digestive
chronic stages of the disease.6,7 Additionally, female infants may perpetuate the
multigenerational, vertical transmission of Chagas disease.6
Congenital T. cruzi transmission cannot be prevented by treating a mother during pregnancy
since the teratogenic risks of anti-parasitic treatment (benznidazole and nifurtimox) are not
well known and the risk of adverse reactions is high in adults.8 However, infected newborns
diagnosed and treated during the first year of life have nearly a 100% chance of
parasitological cure and low risk of adverse events.8–12 Thus, active screening of pregnant
women from endemic areas and early screening of infants is particularly important in
improving health outcomes of infants.
The rate of transmission from infected mother to infant remains to be summarized
quantitatively. In the Southern Cone countries of Latin America (the endemic region), the
reported rates of congenital T. cruzi transmission vary from 1% to 12%.13 In contrast, very
little is known about congenital transmission rates in Mexico, Central America6 and in non-
Howard et al. Page 2
BJOG. Author manuscript; available in PMC 2015 January 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
endemic countries. A theoretical study estimated that about 40,000 pregnant women and
2,000 newborns could be infected by T. cruzi in Canada, Mexico and the United States.14
Understanding the frequency of congenital T. cruzi transmission is important for the
continued implementation of screening for pregnant women and early treatment programs
for infected newborns. The objectives of this study are to calculate a pooled congenital
transmission rate and to describe the rate of transmission by the endemicity of the region and
the method of diagnosis of congenital infection. This study systematically reviews the
literature for original observational studies and case reports that describe the frequency of
congenital T. cruzi transmission.
Methods
Eligibility Criteria
The study population consisted of pregnant or recently pregnant women who are infected
with T. cruzi and their infants. The objective is to assess how often the outcome - congenital
transmission of the parasite to their infants – is occurring. Studies included in this systematic
review and meta-analysis have different methods of diagnosing congenitally transmitted T.
cruzi infection in infants. Definitive diagnosis can be made using one or a combination of
the following two techniques: (i) parasitological examination of umbilical cord blood or
venous blood of the infant at any time after birth and (ii) detecting T. cruzi-specific
antibodies using serological tests on an infant’s blood sample >8 months of age (when
maternal antibodies have disappeared).8 Other methods of diagnosis sometimes employed or
combined with the methods above are polymerase chain reaction (PCR) of the umbilical
cord or infant blood sample, hemoculture and xenodiagnosis.
All published research was considered regardless of publication type (e.g. abstract, poster,
and article). We included prospective and retrospective observational study designs, as well
as case reports. There were no restrictions on time period or limits placed on language at the
time of the search, which was completed on October 24, 2012.
Information Sources & Search Strategy
The databases PubMed, Journals@Ovid Full Text, EMBASE, CINAHL (EBSCO), Fuente
Academica (EBSCO) and BIREME were chosen for the literature search so as to include as
many Latin American studies as possible. The search terms used were “Trypanosoma cruzi
OR Chagas AND transmission AND pregnancy,” “congenital AND Trypanosoma cruzi
infection,” “congenital AND Chagas infection,” “vertical transmission AND Trypanosoma
cruzi,” “vertical transmission AND Chagas,” “maternal fetal transmission AND
Trypanosoma cruzi,” and “maternal fetal transmission AND Chagas.”
Refworks was used to merge retrieved citations and eliminate duplicates. Authors were
contacted if the full-text article could not be acquired by library services or when there were
questions about the study’s methods.
Study Selection Criteria
The following inclusion/exclusion criteria were used to select the studies: (i) study is in
Dutch, English, French, Portuguese, Spanish; (ii) study is a case report, case series, or
observational study (i.e., case-control, cross-sectional, cohort); (iii) study presents original
data on congenital T. cruzi infection in humans; (iv) the congenital infection rate was
reported or it could be derived from data presented. Review articles and articles that
employed only placental histopathology as a method of diagnosis were excluded because the
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placental defenses are able to contend parasitic infection before it occurs in the neonate. The
presence of parasites in the placenta does not confirm a congenital infection.6
All database search results were considered for inclusion. First, duplicate records were
removed. Abstracts were reviewed to determine study eligibility, based upon the above
inclusion criteria. Finally, the full-text of the studies was compiled for final review. In an
effort to exclude articles with overlapping cohorts, all of the articles’ study populations, time
periods, and sample sizes were reviewed, given our knowledge of the co-authors and
affiliations. When articles with duplicate data were discovered, the article with the greatest
sample size was chosen for inclusion.
Data Collection Process & Data Items
A data abstraction form was created a priori and information relevant to the study research
question was extracted independently by two investigators. Where there were data
discrepancies, the investigators met for discussion until a consensus was made. The
following data was collected: author, publication year, and country, sample size, study
design (case report, case series, or comparative), study setting (hospital, multi-hospital,
population, multi-national, etc.), characteristics of the study (country, endemic/non-
endemic), method of diagnosis of congenital infection (e.g. parasitology, serology, PCR),
timing of diagnosis (e.g. birth, 8 months, 1 year of age), origin of the diagnostic blood
sample (e.g. umbilical cord, heel prick, venous blood), and the congenital infection rate (or
the data required to calculate it).
Comparative studies were distinguished as prospective or retrospective observational
studies. Non-endemic countries are defined as those where vector transmission to man either
does not occur or remains limited, as in the United States, Canada and European countries.
Bias Assessment
Study quality was assessed through stratification of studies during subgroup analysis. A
Begg’s funnel plot of the natural logarithm of the rates versus their standard errors was used
to assess for publication bias. An Egger’s regression test was also conducted.
Data Analysis
The principal summary measure is the congenital transmission rate, which is defined as the
number of congenitally infected infants divided by the number of infants born to infected
mothers. Where the transmission rate was not reported, the investigators calculated one from
the information reported. Case reports and case series were not included in the calculation of
a summary statistic. If the number of events and sample size could not be calculated, the
study could not be included in the meta-analysis.
The pooled congenital transmission rates and 95% confidence intervals (CI) were first
calculated using a fixed effects model. The heterogeneity between studies was assessed with
the Dersimonian and Laird’s Q test and I2 statistic.15 A random effects model was used
based on the results.
Two subgroup analyses were planned a priori considering the diagnostic method and
endemicity. In the first subgroup analysis, the studies were stratified into three groups based
on the diagnostic method that was used when diagnosing the congenital infection: (i)
parasitology at any time and/or serology after 8 months of age (the reference standards), (ii)
PCR and (iii) mixed or other methods. Any studies that performed the serological tests
before 8 months of age (without parasitology) were classified in the “mixed or other
methods” category due the possible presence of maternal antibodies and thus false positive
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tests.16 If the study reported multiple congenital transmission rates by different methods of
diagnosis, we averaged the method-specific rates for inclusion in the pooled analysis and
used the separated results in the appropriate subgroup analysis. For the second subgroup
analysis, the studies were compared by the endemicity of the country or region in which the
study was completed. This is important because individuals in non-endemic countries will
have no exposure/re-exposure to vector transmission, the primary mode of transmission,
thus decreasing the mother’s parasite load. A sensitivity analysis assessed the effect of
excluding studies that reported zero outcomes (congenital infections).
All statistical analyses were performed within Microsoft Excel using a previously
constructed spreadsheet for generating a descriptive summary statistic and forest plots.17 We
have adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) guidelines and Meta-analysis Of Observational Studies in Epidemiology
(MOOSE) checklist for reporting.18,19
Results
Of the 256 abstracts retained after duplicates were removed, 96 were excluded because the
abstracts indicated the research was not a qualifying study design (case report, case series, or
comparative study) or was not completed in humans. One hundred sixty full-text articles
were assessed for eligibility. Ninety-five articles did not qualify for inclusion for the
following reasons: unoriginal data, not about congenital transmission of Chagas, or an
inability to calculate a rate from the data presented. Thirteen studies were case-reports or
case series. One study could not be included in the meta-analysis because the number of
events and sample size were not reported and could not be calculated. The systematic review
and meta-analysis included 64 and 51 articles, respectively (Figure 1).
Eleven case reports and two case series for a total of 14 congenital infections out of 18 births
are described in Table 1. Six of the reports are from non-endemic countries.20–25 One case
report summarized diagnosis in two of three triamniotic, dichorionic infants sharing a
placenta, which lends support to the placental mode of transmission.26 Most of the
diagnoses were made at birth or within one month of age (n=8); however, timing of
diagnosis ranged from prenatal27 to 7 years of age.28 The method of diagnosis was mixed in
all but one case, where only serology was used.29 Nine case reports included direct
microscopy in combination with serology, PCR, culture, xenodiagnosis, and/or
symptomatology.
Twenty-one of the 51 observational studies were conducted in non-endemic countries, with
the majority (86%) from Spain. All but five of the studies used a prospective study design.
Five studies of the 51 studies provided more than one estimate of congenital transmission by
different methods of diagnosis. Twenty-two studies (43%) diagnosed congenital T. cruzi
infection according to the reference standard: direct microscopy at any age and/or serology
at >8 months of age. PCR only was used by nine of the studies to assess the rate of
congenital infection. The remainder (n=27) made the diagnosis with other or mixed
methods, including one or a combination of direct microscopy, serology, PCR, hemoculture,
and xenodiagnoses. Sample sizes varied greatly from 130,31 to 4377 infants,32 while the
number of diagnosed congenital cases ranged from 0 (n=13 studies) to 267 infants.32 After
excluding the studies without congenital infections, the congenital transmission rates ranged
from 0.75%33 to 28.6%.34 Characteristics of the observational studies included in the meta-
analysis are presented in Table 2.
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Meta-analysis
Fifty-one studies were selected for inclusion in the meta-analysis. A fixed effects method of
analysis did not fit the data well, therefore, a random effects model was used with a
continuity correction of 0.5 added to each study with zero events (Q=45.5, P<0.01, I2=0,
df=50). We estimated a pooled congenital T. cruzi transmission risk of 0.047 (95% CI:
0.039–0.056) or 4.7% (95% CI: 3.9–5.6%) (Figure 2).
Subgroup & Sensitivity Analyses
The method of diagnosis subgroup analysis resulted in pooled, random effects estimates of
4.6% (95% CI: 3.4–5.7%) for the reference standard, 6.0% (95% CI: 4.3–7.7%) for PCR,
and 4.5% (95% CI: 3.4–5.5%) for mixed/other methods of diagnosis. Countries or regions
that are disease endemic with the potential for vector transmission were almost two times as
likely to have congenital transmission (5.0% vs. 2.7%). Removing the studies that reported
no cases of congenital transmission slightly increased the pooled estimate of congenital
infection risk compared to leaving the study in and adding a continuity correction (4.8% vs.
4.7%). The results of the subgroup and sensitivity analyses and their accompanying
heterogeneity statistics can be found in Table 3.
Bias Assessment
The 51 estimates of T. cruzi congenital transmission were used to generate a Begg’s funnel
plot to assess for publication bias. This visual plot (Figure 3) shows a symmetrical
distribution of points (natural log transformed rates plotted against the standard error of the
rates. The plot and non-significant Egger’s regression test (p=0.20) indicate a lack of
publication bias.
Discussion
Main Findings
This systematic review included 13 case reports or case series and 51 observational studies.
We found a pooled rate of congenital transmission of 0.047. This means that in a population
of T. cruzi infected mothers, 5% of the infants may be congenitally infected. This finding is
consistent with the widely accepted 1–12% range of congenital transmission rates that is
frequently reported in the literature.13 When studies with zero cases of congenital
transmission were excluded, the rate increased to 4.8% (95% CI: 4.0–5.7%) of infants.
Subgroup analysis by method of diagnosis found the greatest rate of transmission among
studies that used PCR, followed by direct microscopy and/or serology, and finally, mixed or
other techniques (6.0% vs. 4.6% vs. 4.5%, respectively). Studies conducted in endemic
countries or regions compared to non-endemic were more likely to find a higher rate of
congenital transmission (5.0% vs. 2.7%).
Interpretation
Our subgroup analysis estimate for studies that used direct parasitology and/or serology after
8 months for diagnosis represents a conservative estimate of the rate of congenital
transmission of T. cruzi (4.6% (95% CI: 3.4–5.7%)). Direct parasitological methods are
highly specific and definitively confirm congenital infection, but they can have a lower
sensitivity due to low parasitemia or an inexperienced technician.6,35 Additionally, loss to
follow-up results in fewer additional blood samples for microscopy detection and
confirmatory serology. Bern and colleagues estimated that one-half of all congenital
infections are missed.35
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The pooled congenital transmission rate for studies utilizing PCR for diagnosis was higher
than that of the subgroup that used direct microscopy and/or serology (6.0% vs. 4.6%). This
finding is supported by recent literature suggesting that PCR is more sensitive and detects
congenital infections earlier than conventional techniques.10,36,37 However, PCR has not yet
been validated for clinical diagnosis of congenital infection.8 Positive PCR results on infant
blood indicate fetal exposure to T. cruzi, however, trace amounts of parasite DNA, derived
from lysed parasites, may also trigger a positive test result. Additionally, it has been
suggested that some infected fetuses may be able to “self-cure” their infection.6 Therefore, a
positive PCR result at birth can hardly be interpreted as indicative of an active infection.
Indeed, a positive PCR result can indicate an active infection, but this is not obligatory,
especially when only traces are detected. Direct examination and/or late serology after 8
months of age are needed to confirm congenital infection.8
Infected mothers can be either in the acute phase (a recent infection displaying mild or no
symptoms), characterized by easily detectable parasitemia, or the chronic phase where
relatively few parasites can be found in the blood. Although most studies did not report the
mothers’ phase of infection, most mothers in our included studies were likely in the chronic
phase since the acute phase only lasts a few months. Interestingly, the case series by Moretti
and colleagues reports three cases of acute maternal infection with one case of congenital
transmission occurring from a mother infected earlier in pregnancy.38 Other studies report
that mothers of infected infants had higher parasite loads than seropositive mothers of
uninfected infants.35,39,40
On a similar note, during pregnancy, the maternal immune system becomes temporarily
depressed in order to prevent fetus rejection and continue the pregnancy.41 Mothers who
transmit T. cruzi have lower specific T-cell-mediated immune responses and produce less
interferon gamma (IFN-γ). This immune modulation could favor higher parasitemias in the
mothers and the subsequent congenital transmission.39 A strongly depressed immune system
may be responsible for the 100% congenital transmission rate observed among infants born
to HIV positive mothers (3 of 3) in our included study by Scapellato and colleagues.42
Reduction of parasitemia and prevention of future congenital transmission may be feasible
through the etiological treatment of infected young women prior to pregnancy.43 In this
study by Sosa-Estani and colleagues, which diagnosed congenital infection using the
reference standard, no cases of congenital infection were found in 32 infants born to 16
women previously treated with benznidazole.
In this analysis, studies of infants born in endemic countries were more likely to find
congenital transmission in their population. This may be partly due to vector transmission in
infants during the first few months after birth that are incorrectly attributed to congenital
transmission. Further analysis of the studies that used only direct microscopy in the first few
days of life (n=6) was not possible since all of the studies were in endemic regions (i.e. no
comparison rate could be calculated for non-endemic regions). However, more probable is
that continued exposure to infected vectors in endemic regions contributes to increases in
maternal parasitemia, which results in an increased risk of congenital
transmission.38,39,44–46 In the absence of vectors and infected blood transfusions, the
propagation of T. cruzi infection is dependent upon transgenerational vertical transmission.
Burgos and colleagues described a case of triplets where two of the infants who shared a
placenta were born congenitally infected.26 Familial clustering has also been described
elsewhere.6,9,47–50
The included studies from non-endemic countries had a wider range of rates (0–28.6%)
compared to the endemic regions (0–17%), which may be the result of a combination of
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smaller sample sizes and random chance, but may also be related to the country of origin of
the immigrants in these non-endemic countries. Further research in this area is necessary.
Additionally, there is a paucity of studies on the congenital transmission of T. cruzi in
Central America in the literature. This meta-analysis only identified two studies from
Mexico, both of which were very small. Therefore, the pooled transmission rate may not
describe the situation in Central America and Mexico, or other regions under-represented in
the literature.
Strengths and Limitations
The strengths of this systematic review include searching databases that are primarily
devoted to Latin American research and performing strict sub-group analyses by the method
of diagnosis. Also, there was no indication of publication bias which supports our thorough
search strategy. The limitations are that we did not always have explicit method and timing
of diagnosis information, which meant that some studies which may have used the reference
standard were included in the mixed/other subgroup analysis. Similarly, we did not stratify
the studies that used PCR by the age at which the test was done which may have resulted in
some heterogeneity. Often, the age at which the blood sample was taken for PCR analysis
was not stated.
A quality assessment of the selected studies was not completed due to lack of variation in
key indicators of quality. For instance, all the studies were observational; there were no
randomized trials and since the meta-analysis utilized rates, not ratios, there are no
unexposed groups to assess. Additionally, the outcome assessment for all studies was
objectively assessed even though the methods of diagnosis may have been different.
Another important limitation is the possibility of duplication of data. However, the included
studies’ methods were thoroughly reviewed for overlapping study populations and articles
were excluded as necessary. Even with studies from different time periods, it is possible that
the same women may be included in more than one study during different pregnancies, as
may be the case with the two studies by de Rissio and colleagues.32,51 Lastly, vector
transmission cannot be ruled out as a source of infant infection in many of our included
studies from endemic regions. This is a problem intrinsic to all studies diagnosing congenital
T. cruzi infection, except those diagnosing infection with direct parasitological methods at
birth.
Conclusion
Congenital transmission of Chagas disease is a global problem. The subgroup and sensitivity
analyses provide confidence that congenital infection is occurring in about 5% of infants
born to infected mothers. Countries or regions that are disease endemic with the potential for
vector transmission to man may be more likely to have congenital transmission. While
continued vector control activities and surveillance of blood and tissue banks is beneficial,
the congenital mode of transmission requires targeted screening in order to prevent future
cases of Chagas disease.
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Figure 1.
PRISMA flow diagram of study selection process.
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Figure 2.
Forest plot of congenital T. cruzi transmission rates of the included studies and effect
summary. A random effects model was used with a continuity correction of 0.5 added to
each study with zero events (Q=45.5, P<0.01, I2=0, df=50). The effect summary includes 51
estimates of congenital transmission, for a total of 819 cases of congenital transmission from
16,537 infants of infected mothers.
Howard et al. Page 16
BJOG. Author manuscript; available in PMC 2015 January 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 3.
Funnel plot, using data from 51 studies of the rate of T. cruzi congenital transmission plotted
against the standard error of the rate.
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